Sirna Therapeutics has inked a drug development pact with GSK to develop RNAi therapies for respiratory diseases. In the deal, Sirna gains $12 million up front and up to $700 million in additional milestone payments.
"By combining GSK's pulmonary drug delivery expertise with Sirna's advanced application of RNAi technology, this alliance will expedite the development of novel therapeutics with potential use in a number of respiratory diseases such as asthma and COPD," said Dr. Garth Rapeport, senior vice president, respiratory and inflammation CEDD, at GSK.
- check out the release for more